Skip to main content
FinSpry Logo
FinSpry
HALO logo
HALO
(NASDAQ)
Halozyme Therapeutics, Inc.
$110.19-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Halozyme Therapeutics (HALO) Stock Price & Financial Analysis

Halozyme Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$109.00 - $111.15
52-Week High$111.15
52-Week Low$61.23
Open$109.91
Volume956.34K
Average Volume (3M)2.12M
Market Cap13.54B
Shares Outstanding122.88M
P/E Ratio (TTM)38.81
Forward P/E53.51
Price to Sales (P/S)8.98
Price to Book (P/B)61.65
EV/EBITDA24.86
Revenue (TTM)1.51B
Net Income (TTM)348.84M
Free Cash Flow (TTM)667.65M
EPS (TTM)$2.87
Profit Margin23.13%
Operating Margin56.96%
Return on Equity (ROE)158.83%
Debt to Equity9.76
50-Day MA$90.67
200-Day MA$74.21
52-Week Change47.06%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Halozyme Therapeutics

What is the current stock price for HALO?

As of the latest trading session, HALO stock trades at $110.19. The 52-week range is $61.23–$111.15, with a day range of $109.00–$111.15.

What is the P/E ratio for HALO?

Halozyme Therapeutics's trailing P/E ratio is 38.8, meaning investors pay $38.8 for every $1 of annual earnings. The forward P/E is 53.5, reflecting analyst expectations for future earnings. Halozyme Therapeutics operates in the Healthcare sector.

Does HALO pay dividends?

Halozyme Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for HALO?

Based on 4 analysts, the consensus for HALO is Buy.

What is the market cap of HALO?

Halozyme Therapeutics's market capitalization is $13.54B, classifying it as a large-cap company. Halozyme Therapeutics operates in the Healthcare sector within the Biotechnology industry.